OBJECTIVES: To determine whether repeated administration of the macrocyclic gadolinium-based contrast agent (GBCA) gadobutrol in children is associated with T1-weighted hyperintensity within the dentate nucleus, an imaging surrogate for gadolinium deposition. METHODS: With institutional review board approval, we identified a cohort of eight patients aged 18 years or younger who underwent at least four gadobutrol-enhanced magnetic resonance imaging (MRI) examinations of the brain from 2013 to 2017. For comparison, we identified a cohort of 19 patients who underwent at least four gadopentetate dimeglumine-enhanced MRI examinations. For each examination, both dentate nuclei were contoured on unenhanced images; the mean dentate-to-pons signal intensity (DN-P SI) ratio was calculated. DN-P SI ratios from the first and last MRI exams were compared using Wilcoxon signed ranks tests and linear regression analyses. RESULTS: In the gadobutrol cohort, there was no significant change in the mean DN-P SI ratio from the first to the last scan (1.02 vs 1.02, p = 1.00). In the gadopentetate dimeglumine cohort, there was a significant increase in the mean DN-P SI ratio from the first to the last scan (1.05 vs 1.13, p = 0.003). After controlling for potentially confounding variables, the change in DN-P SI ratio from the first to the last scan was significantly lower for patients in the gadobutrol group than in the gadopentetate dimeglumine group (β = -0.08, p = 0.04). CONCLUSIONS: Repeated administration of the macrocyclic GBCA gadobutrol in children was not associated with T1-weighted dentate hyperintensity, while the repeated administration of the linear GBCA gadopentetate dimeglumine was associated with T1-weighted dentate hyperintensity, presumably due to gadolinium deposition. KEY POINTS: • Gadolinium-based contrast agents are routinely used in magnetic resonance imaging. • Repeated administration of the macrocyclic agent gadobutrol in children was not associated with T1-weighted dentate hyperintensity.
OBJECTIVES: To determine whether repeated administration of the macrocyclic gadolinium-based contrast agent (GBCA) gadobutrol in children is associated with T1-weighted hyperintensity within the dentate nucleus, an imaging surrogate for gadolinium deposition. METHODS: With institutional review board approval, we identified a cohort of eight patients aged 18 years or younger who underwent at least four gadobutrol-enhanced magnetic resonance imaging (MRI) examinations of the brain from 2013 to 2017. For comparison, we identified a cohort of 19 patients who underwent at least four gadopentetate dimeglumine-enhanced MRI examinations. For each examination, both dentate nuclei were contoured on unenhanced images; the mean dentate-to-pons signal intensity (DN-P SI) ratio was calculated. DN-P SI ratios from the first and last MRI exams were compared using Wilcoxon signed ranks tests and linear regression analyses. RESULTS: In the gadobutrol cohort, there was no significant change in the mean DN-P SI ratio from the first to the last scan (1.02 vs 1.02, p = 1.00). In the gadopentetate dimeglumine cohort, there was a significant increase in the mean DN-P SI ratio from the first to the last scan (1.05 vs 1.13, p = 0.003). After controlling for potentially confounding variables, the change in DN-P SI ratio from the first to the last scan was significantly lower for patients in the gadobutrol group than in the gadopentetate dimeglumine group (β = -0.08, p = 0.04). CONCLUSIONS: Repeated administration of the macrocyclic GBCAgadobutrol in children was not associated with T1-weighted dentate hyperintensity, while the repeated administration of the linear GBCAgadopentetate dimeglumine was associated with T1-weighted dentate hyperintensity, presumably due to gadolinium deposition. KEY POINTS: • Gadolinium-based contrast agents are routinely used in magnetic resonance imaging. • Repeated administration of the macrocyclic agent gadobutrol in children was not associated with T1-weighted dentate hyperintensity.
Entities:
Keywords:
Cerebellar nuclei; Contrast media; Gadolinium; Magnetic resonance imaging; Paediatrics
Authors: Young Jin Ryu; Young Hun Choi; Jung-Eun Cheon; Woo-Jin Lee; Subin Park; Ji Eun Park; Woo Sun Kim; In-One Kim Journal: Invest Radiol Date: 2018-04 Impact factor: 6.016
Authors: Alexander Radbruch; Lukas D Weberling; Pascal J Kieslich; Oliver Eidel; Sina Burth; Philipp Kickingereder; Sabine Heiland; Wolfgang Wick; Heinz-Peter Schlemmer; Martin Bendszus Journal: Radiology Date: 2015-04-06 Impact factor: 11.105
Authors: Alexander Radbruch; Robert Haase; Pascal J Kieslich; Lukas D Weberling; Philipp Kickingereder; Wolfgang Wick; Heinz-Peter Schlemmer; Martin Bendszus Journal: Radiology Date: 2016-12-07 Impact factor: 11.105
Authors: Yuri Errante; Vincenzo Cirimele; Carlo Augusto Mallio; Vincenzo Di Lazzaro; Bruno Beomonte Zobel; Carlo Cosimo Quattrocchi Journal: Invest Radiol Date: 2014-10 Impact factor: 6.016
Authors: Alexander Radbruch; Robert Haase; Philipp Kickingereder; Philipp Bäumer; Sebastian Bickelhaupt; Daniel Paech; Wolfgang Wick; Heinz-Peter Schlemmer; Angelika Seitz; Martin Bendszus Journal: Radiology Date: 2017-03-08 Impact factor: 11.105
Authors: Maria Camilla Rossi Espagnet; Bruno Bernardi; Luca Pasquini; Lorenzo Figà-Talamanca; Paolo Tomà; Antonio Napolitano Journal: Pediatr Radiol Date: 2017-05-19
Authors: Robert J McDonald; Jennifer S McDonald; David F Kallmes; Mark E Jentoft; Michael A Paolini; David L Murray; Eric E Williamson; Laurence J Eckel Journal: Radiology Date: 2017-06-27 Impact factor: 11.105
Authors: Diane M Renz; Stefanie Kümpel; Joachim Böttcher; Alexander Pfeil; Florian Streitparth; Matthias Waginger; Jürgen R Reichenbach; Ulf K Teichgräber; Hans-Joachim Mentzel Journal: Invest Radiol Date: 2018-02 Impact factor: 6.016
Authors: Carlo C Quattrocchi; Joana Ramalho; Aart J van der Molen; Àlex Rovira; Alexander Radbruch Journal: Eur Radiol Date: 2018-11-09 Impact factor: 5.315
Authors: Makoto Hasegawa; Brianne R Duncan; Desiree A Marshall; Luis F Gonzalez-Cuyar; Michael Paulsen; Masahiro Kobayashi; Christopher Simpson; Kenneth R Maravilla Journal: Invest Radiol Date: 2020-10 Impact factor: 10.065